09:58 AM EST - Eupraxia Pharmaceuticals Inc. : Announced additional positive clinical data from its RESOLVE Phase 1b/2a trial, which is evaluating the safety and efficacy of EP-104GI as a treatment for eosinophilic esophagitis. Eupraxia Pharmaceuticals Inc.
shares T.EPRX are trading up $0.34 at $3.69.
